Hoth Therapeutics Announces Merger with Algorithm Sciences, Inc. to Focus on Pulmonary Arterial Hypertension (PAH) and Appoints Mike Tilton as CEO
Leadership Changes
April 26, 2023
April 26, 2023
Hoth Therapeutics, Inc. (HOTH), a patient-focused biopharmaceutical company, has recently announced that it has signed a Letter of Intent to merge with Algorithm Sciences, Inc. The new company will take on the Algorithm Sciences, Inc. name and will be focused on Pulmonary Arterial Hypertension (PAH).
As part of the merger, the new company will be led by experienced biopharma executives. Mike Tilton has been appointed as the CEO, while David Cavalier will serve as the CFO. Anthony Zook, Algorithm's current chairman of the board, will be nominated as the chairman of the combined company's board of directors.
Mike Tilton, the new CEO of Algorithm Sciences, Inc., brings over 25 years of experience in the pharmaceutical industry. He has held various leadership positions in companies such as Bristol Myers Squibb and Novartis, where he worked on drug development, commercialization, and strategy.
Members of LevelFields received the alert of this event on April 26, 8:45 AM ET
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions,and let LevelFields help you become a better trader.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better trader.